Company Encyclopedia
View More
name
OBiO Tech
688238.SH
Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. The company was founded in 2013 and is headquartered in Shanghai, China.
569.19 B
688238.SHMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking26/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-17.56%E
    • Profit Margin-120.24%E
    • Gross Margin-21.06%E
  • Growth ScoreD
    • Revenue YoY-2.80%D
    • Net Profit YoY-19.28%D
    • Total Assets YoY-10.04%E
    • Net Assets YoY-20.71%E
  • Cash ScoreD
    • Cash Flow Margin-83.16%D
    • OCF YoY-2.80%D
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreB
    • Gearing Ratio30.03%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    OBiO Tech: Net loss of 105 million yuan in the first half of 2025, a year-on-year narrowing

    OBiO Tech announced that its operating revenue in the first half of 2025 was 120 million yuan, a year-on-year increase of 6.01%. The net loss attributable to shareholders of the listed company was 105 million yuan, compared to a net loss of 113 million yuan in the same period last year

    Zhitong·
    SH
    688238
    -1.47%
    Zhitong·
    SH
    688238
    -1.47%

    OBiO Tech plans to promote a restricted stock incentive plan of 3.7454 million shares

    According to the Zhitong Finance APP, OBiO Tech disclosed its 2025 Restricted Stock Incentive Plan (draft), proposing to grant a total of 3.7454 million restricted shares to the incentive recipients, accounting for approximately 0.58% of the company's total equity on the announcement date of the incentive plan draft. Among them, 2.9964 million restricted shares will be granted in the first grant, with a total of 61 recipients for the first grant, and the grant price is set at 3.09 yuan/share

    Zhitong·
    SH
    688238
    -1.47%
    Zhitong·
    SH
    688238
    -1.47%

    Zhengzhou Airport Economic Zone in Henan and OBiO Tech have strategic cooperation plans to build a "cell factory" and pilot the development of the cell gene therapy industry

    According to reporters from the Zhengzhou Airport Economic Zone Management Committee in Henan, recently, the Management Committee of the Airport Economic Zone signed a cooperation agreement with OBiO Tech, and both parties conducted in-depth exchanges on matters such as the construction of a "cell factory" and the "pilot program" for the development of the cell and gene therapy industry

    Zhitong·
    SH
    688238
    -1.47%
    Zhitong·
    SH
    688238
    -1.47%

    OBiO Tech shareholder Huairuishengyin and its concerted parties plan to reduce their holdings by no more than 1%

    According to the Zhitong Finance APP, OBiO Tech announced that its shareholder Huairuishengyin and its concerted parties plan to reduce their holdings in the company through centralized bidding and block trading, with the total number of shares to be reduced not exceeding 6.4904 million shares, accounting for no more than 1% of the company's total share capital

    Zhitong·
    SH
    688238
    -1.47%
    Zhitong·
    SH
    688238
    -1.47%

    CRO concept stocks fluctuate and strengthen, PR rises over 10%

    36Kr learned that as of the time of publication, CRO concept stocks have fluctuated and strengthened, with PR rising over 10%, and Asymchem, WuXi AppTec, ChemPartner, Pharmaron, and OBiO Tech among the top gainers

    36Kr·
    SH
    603259
    +0.83%
    HK
    02359
    +0.10%
    SZ
    300149
    -1.43%
    36Kr·
    SH
    603259
    +0.83%
    HK
    02359
    +0.10%
    SZ
    300149
    -1.43%
    © 2025 Longbridge｜Disclaimer